Prof. Dr. Stefan Dübel
Stefan Dübel is full Professor of Biotechnology and Director of the respective department at the Technische Universität Braunschweig, Germany. He further serves as director of the technology transfer unit "Centre for Molecular Engineering" of iTUBSmbH and as consultant to biotech / pharma companies and US/EU goverment institutions. He initiated the "Antibody factory" of the German National Gemome Research Network and is editor of the four volume "Handbook of Therapeutic Antibodies" and other antibody engineering books. He is co-founder of several biotech companies, including the animal-free antibody company Abcalis and the human therapeutic antibody discovery and antibody engineering company Yumab. He was further instumental in the creation of the Corona Antibody Team and CORAT Therapeutics GmbH, developing a passive vaccine against SARS-CoV-2 for direct treatment of COVID-19.
After obtaining his Ph.D. from the Universitiy of Heidelberg, in 1989 he joined the German Cancer Research Center (DKFZ) where he co-pioneered in vitro antibody selection technologies, resulting in several key inventions including antibody phage display (e.g. US Patent 5849500), human antibody libraries (e.g. US Patent 6319690) and antibody libraries with randomised CDRs (e.g. US Patent 5840479). His lab continued to contribute multiple innovations to human antibody engineering, phage display and in vitro evolution, e.g. Hyperphage technology (2001), ORFeome display (2006), and targeted RNases for cancer therapy (1995/2008). Further achievements include the development of the first protein knock down mouse using intrabodies (2014), a universal allosteric switch module for antibody affinity (2017) and multiclonal antibodies (2019). His work resulted in >250 publications and >25 patent applications.
Antibody Engineering, Phage Display, anti-cancer-Antibodies, Intrabodies, in vitro Evolution, Synthetic Biology, Biosensors, Sneaking Ligands, Hyperphage, SARS-CoV-2 neutralizing antibodies
1978-1982 Studies of Biology at the Universities of Mainz and Heidelberg, Germany
1982-1983 Diploma thesis in Botany at the Max-Planck Institute for Cell Biology in Ladenburg, Germany on "Developmental Biology of the Green Algae Acetabularia"
1984-1985 Zivildienst: Research on "Diagnostic Tools for Autoimmune Diseases" at the Institute of Immunology, University of Heidelberg.
1986-1989 PhD thesis at the Centre for Molecular Biologiy Heidelberg (ZMBH) on "Cell Cycle Regulation and Cell Differentiation in the Coelenterate Hydra", Promotion (Dr. rer. nat.) summa cum laude.
8/1989-7/1991 Post-Doc at the German Cancer Research Centre, Heidelberg (DKFZ) with a project on "Generation and Screening of E. coli Libraries of Recombinant Antibodies"
1/1992-7/1992 Work on "Recombinant Antibodies Against TNF Receptor" at the Institute of Cell Biology and Immunology, University of Stuttgart, Germany
8/1992-9/1996 Work on "Recombinant Antibodies, Immunotoxins and Phage Display Screening Technologies" at the German Cancer Research Centre, Heidelberg (DKFZ)
1996-2001 Group leader of the "Recombinant Antibody Unit" at the Department of Molecular Genetics, University of Heidelberg
6/1997 Habilitation (Faculty of Biology), University of Heidelberg
2/2001 Appointed "Hochschuldozent" at the University of Heidelberg
2001-2002 CSO and Member of the Directory Board of LifeBits AG
Oct 2002 - today Full Professor and Director of the Department of Biotechnology, Technical University of Braunschweig, Germany
1989 "Stipendium zur Förderung des herausragenden wissenschaftlichen Nachwuchses" des Deutschen Krebsforschungszentrums Heidelberg